Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents

被引：14

作者：

Lu, X. -L. ^{[1
]}

Cao, X. ^{[2
]}

Liu, X. -Y. ^{[1
]}

Jiao, B. -H. ^{[1
]}

机构：

[1] Second Mil Med Univ, Dept Biochem & Mol Biol, Fac Basic Med Sci, Shanghai 200433, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai 200032, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2010年 / 17卷 / 12期

关键词：

Protein tyrosine kinases; Src kinases; SH2; SH3; inhibitor; peptidomimetic; nonpeptide; progress; GROWTH-FACTOR RECEPTOR; STRUCTURE-BASED DESIGN; NONPEPTIDE INHIBITORS; TYROSINE KINASE; SMALL-MOLECULE; ACTIVATED SRC; LIGANDS; CELL; BINDING; CANCER;

D O I：

10.2174/092986710790827861

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Src family tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. For both Src SH2 and SH3 domains involve in the regulation of tumorigenesis signal pathways, the SH2 and SH3 inhibition strategies are expected to block the protein-protein interactions between SFKs and their corporation proteins to abolish the signal transduction. Many inhibitors of SH2 and SH3 domain have been identified. Herein, some predominant examples of these inhibitors are reviewed.

引用

页码：1117 / 1124

页数：8

共 50 条

[31] Simultaneous assay of Src SH3 and SH2 domain binding using different wavelength fluorescence polarization probes
Lynch, BA
Minor, C
Loiacono, KA
van Schravendijk, MR
Ram, MK
Sundaramoorthi, R
Adams, SE
Phillips, T
Holt, D
Rickles, RJ
MacNeil, IA
ANALYTICAL BIOCHEMISTRY, 1999, 275 (01) : 62 - 73
[32] SH2 AND SH3 DOMAINS AS MOLECULAR ADHESIVES - THE INTERACTIONS OF CRK AND ABL
FELLER, SM
REN, RB
HANAFUSA, H
BALTIMORE, D
TRENDS IN BIOCHEMICAL SCIENCES, 1994, 19 (11) : 453 - 458
[33] Design of tetrapeptide ligands as inhibitors of the Src SH2 domain
Nam, NH
Pitts, RL
Sun, GQ
Sardari, S
Tiemo, A
Xie, MX
Yan, BF
Parang, K
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (04) : 779 - 787
[34] EFFECTS OF SH2 AND SH3 DELETIONS ON THE FUNCTIONAL ACTIVITIES OF WILD-TYPE AND TRANSFORMING VARIANTS OF C-SRC
SEIDELDUGAN, C
MEYER, BE
THOMAS, SM
BRUGGE, JS
MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (04) : 1835 - 1845
[35] c-Src Directly Interacts with the C-terminal Domain of Occludin by involving SH2 and SH3 domains
Seth, Ankur
Samak, Geetha
Zola, Courtney E.
Rao, R. K.
FASEB JOURNAL, 2010, 24
[36] Progress towards the development of SH2 domain inhibitors
Kraskouskaya, Dziyana
Duodu, Eugenia
Arpin, Carolynn C.
Gunning, Patrick T.
CHEMICAL SOCIETY REVIEWS, 2013, 42 (08) : 3337 - 3370
[37] Chemical shift assignments of the partially deuterated Fyn SH2–SH3 domain
Fabien Kieken
Karine Loth
Nico van Nuland
Peter Tompa
Tom Lenaerts
Biomolecular NMR Assignments, 2018, 12 : 117 - 122
[38] SH2 AND SH3 DOMAINS CONTROL PROTEIN INTERACTIONS IN SIGNAL-TRANSDUCTION
PAWSON, T
FASEB JOURNAL, 1994, 8 (07): : A1377 - A1377
[39] SH2 AND SH3 DOMAINS - ELEMENTS THAT CONTROL INTERACTIONS OF CYTOPLASMIC SIGNALING PROTEINS
KOCH, CA
ANDERSON, D
MORAN, MF
ELLIS, C
PAWSON, T
SCIENCE, 1991, 252 (5006) : 668 - 674
[40] A potential SH3 domain-binding site in the Crk SH2 domain
Anafi, M
Rosen, MK
Gish, GD
Kay, LE
Pawson, T
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (35) : 21365 - 21374

← 1 2 3 4 5 →